Don’t let the high cost of brand specialty JAK inhibitor therapy disrupt your treatment. We help eligible patients access Olumiant (baricitinib) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Olumiant Patient Assistance Program is run by the Lilly Cares Foundation, Eli Lilly’s nonprofit patient-assistance arm, and provides Olumiant at no medication cost to qualifying patients — generally for up to 12 months per enrollment, or through the end of the calendar year for Medicare Part D enrollees. Olumiant sits in Lilly Cares’ most generous tier: household income up to 500% of the Federal Poverty Level qualifies ($79,800 for one person, $108,200 for two, $136,600 for three, $165,000 for a family of four), and eligibility extends beyond the uninsured to Medicare Part D enrollees and even Medicare Part B patients without supplemental coverage — though Medicaid, full Extra Help, and VA patients are excluded. Applying directly (1-800-545-6962, Mon–Fri 8 AM–6 PM ET) is always free. The hard part is the documentation, coordination, appeals, and renewal deadlines around it. For a flat $69.95 per month, our Patient Advocates handle every step, from initial application through refills and re-certification.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$5,300 | Save ~$5,230/mo |
| CVS Pharmacy | ~$5,400 | Save ~$5,330/mo |
| Walmart | ~$4,900 | Save ~$4,830/mo |
| Costco | ~$4,850 | Save ~$4,780/mo |
| Specialty Pharmacy | ~$5,000 | Save ~$4,930/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Lilly Cares program is free to apply for and provides Olumiant at no medication cost if approved. Our $69.95/month service covers full advocacy — for patients who want an experienced team managing the process end-to-end, especially with multiple medications, prior denials, or Medicare questions.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Olumiant:
Still $4,800–$5,400 per month even with the best discount
Lilly Cares publishes clear eligibility rules for free Olumiant. You will generally qualify if all of the following are true — and if your situation doesn’t fit neatly, contact AffordMyPrescriptions so we can review your case and determine if you qualify for Olumiant assistance:
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor — a small-molecule tablet that works inside immune cells to interrupt the signaling cascade behind rheumatoid arthritis, severe alopecia areata, and severe COVID-19 inflammation.
How Olumiant Works:
Many inflammatory signals — interleukins, interferons — transmit their message into immune cells through the JAK-STAT pathway. Olumiant selectively inhibits JAK1 and JAK2, dialing down that signaling from inside the cell. Unlike injected biologics, which intercept one inflammatory protein outside cells, a JAK inhibitor works upstream on several at once — which is why one tablet treats conditions as different as joint inflammation and autoimmune hair loss.
Form and Use:
Olumiant is a once-daily oral tablet — 2 mg is the usual dose for rheumatoid arthritis and alopecia areata, with 4 mg used in some alopecia patients and other indications. Being a pill rather than an injection matters practically: no injection training, no refrigeration, ordinary pharmacy dispensing — and for Medicare patients, clean Part D billing under the $2,100 annual cap. It also made history as the first systemic treatment FDA-approved for severe alopecia areata (2022).
Generic Availability:
A generic baricitinib was FDA-approved in August 2025 — but you cannot buy it: Olumiant’s key patents run to around 2029, and no generic has launched. Until one actually reaches pharmacies, there is no lower-cost substitute, and assistance programs remain the practical affordability route. When a generic does launch, prices should fall meaningfully — we track this for our patients.
Warnings:
Olumiant carries boxed warnings shared by the JAK-inhibitor class: serious infections (including tuberculosis — test before starting), increased risk of major cardiovascular events and blood clots, and malignancies including lymphoma, particularly in patients over 50 with cardiovascular risk factors. Report chest pain, leg swelling, shortness of breath, or persistent infections immediately. Your prescriber will monitor blood counts, lipids, and liver enzymes during treatment.
Lilly’s published list price is $2,767.39 per 30-tablet month at the 1 mg or 2 mg strength (the 4 mg strength is double). Eligible patients can receive Olumiant free through the Lilly Cares Foundation; our $69.95 monthly fee covers full advocacy and enrollment management
JAK inhibitors are oral small-molecule drugs that block inflammation signaling inside immune cells, rather than intercepting one inflammatory protein outside them like injected biologics. Olumiant inhibits JAK1 and JAK2 and treats rheumatoid arthritis, severe alopecia areata, and severe COVID-19 in hospitalized patients.
Yes — under Part D as an oral specialty tablet, and the $2,100 annual out-of-pocket cap (2026) limits your total yearly drug spending. Better still, Lilly Cares accepts Medicare Part D enrollees within its income limits — meaning some Medicare patients can get Olumiant entirely free rather than paying toward the cap.
No — the card excludes all government insurance. Medicare patients rely on the Part D cap, Extra Help if income-qualified, or Lilly Cares.
Approved, yes; available, no. FDA approved a generic baricitinib in August 2025, but patents block its launch until around 2029. No lower-cost version can currently be purchased.
Generally up to 12 months, or through the end of the calendar year for Medicare Part D enrollees, with reapplication required. We track your renewal date and re-file before coverage lapses
Denials are usually about documentation — missing income proof, an insurance-status mismatch, or incomplete prescriber sections. Applications can be corrected and resubmitted. We review the denial letter, fix what triggered it, and resubmit on your behalf.
Between Lilly Cares’ 500%-FPL income limit — open to many Medicare patients — the $5 savings card, and the Part D cap, most Olumiant patients have a path to affordable treatment. Check your eligibility today; the pre-qualification review is free, and if we can’t help you, you pay nothing.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.